<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577989</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02251; me20TschudinSutter</org_study_id>
    <nct_id>NCT04577989</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital</brief_title>
  <acronym>AmpCstratBasel</acronym>
  <official_title>Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital (AmpC-strat Basel)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the recent epidemiological trends and the treatment outcome in&#xD;
      terms of the length of hospital stay, the relevant renal and neurological side effects, risk&#xD;
      factors for developing these side effects, the selection of more resistant pathogens under&#xD;
      therapy as well as the incidence of Clostridium difficile infections under treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing resistance among Enterobacterales to beta-lactam antibiotics is globally a major&#xD;
      concern in the antibiotic resistance crisis. In gram-negative bacteria it evolves primarily&#xD;
      through the production of beta-lactamases that allow the rapid hydrolysis of common&#xD;
      antibiotics - most notably 3rd generation cephalosporins. Particularly, the production of&#xD;
      Ambler class C beta-lactamase (AmpC) is a very concerning and unique resistance mechanism as&#xD;
      so called derepressed mutants can be induced during treatment. Information on recent&#xD;
      epidemiological trends as well as comparative information about the treatment strategies&#xD;
      (cefepime versus piperacillin/tazobactam versus carbapenems) for infections with&#xD;
      AmpC-producing Enterobacterales in Switzerland is still lacking. This study is to investigate&#xD;
      the recent epidemiological trends and the treatment outcome in terms of the length of&#xD;
      hospital stay, the relevant renal and neurological side effects, risk factors for developing&#xD;
      these side effects, the selection of more resistant pathogens under therapy as well as the&#xD;
      incidence of Clostridium difficile infections under treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>descriptive analyses of demographic data in patients with detection of AmpC beta-lactamase producing Enterobacterales</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>collection of demographic data (age, gender, hospital admission and discharge date, length of stay, ICU-stay, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel); descriptive analyses summarized as counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>descriptive analyses of clinical data in patients with detection of AmpC beta-lactamase producing Enterobacterales</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>descriptive analyses of clinical data (comorbidities, renal function, previous exposure to antibiotics and proton pump inhibitors, immunosuppressive treatment, date of diagnosis and type of infection with AmpC producing Enterobacterales) summarized as counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>descriptive analyses of treatment data in patients with detection of AmpC beta-lactamase producing Enterobacterales</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>descriptive and comparative analyses of treatment data (empiric and definitive antibiotic therapy including dosage, date of initiation/ discontinuation and changes in antibiotic therapy, exposures to other antimicrobials, concomitant medication, side effects) summarized as counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>descriptive analyses of microbiological data in patients with detection of AmpC beta-lactamase producing Enterobacterales</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>descriptive analyses of microbiological data Species of AmpC producing Enterobacterales, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen, Gram-staining of endotracheal aspirate or bronchoalveolar lavage (BAL), neutrophile and epitheliale cell count, results of culture from sputum, endotracheal aspirate, BAL or lung tissue) summarized as counts</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Infection With AmpC Beta-lactamase Producing Enterobacterales</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in the inpatient setting at the University Hospital Basel from January&#xD;
        1st, 2015 until July 31st, 2020 with detection of AmpC beta-lactamase producing&#xD;
        Enterobacterales&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with detection of AmpC beta-lactamase producing Enterobacterales&#xD;
&#xD;
               1. In a blood culture (any ward)&#xD;
&#xD;
               2. In a clinical sample of the lower respiratory tract (only intensive care unit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with documented refusal of subsequent use of their data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Tschudin Sutter, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Disease and Hospital Epidemiology,University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Tschudin Sutter, Prof. Dr. med.</last_name>
    <phone>+41 061 328 68 10</phone>
    <email>sarah.tschudin@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Herrmann</last_name>
    <email>julia.herrmann@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Infectious Disease and Hospital Epidemiology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Tschudin Sutter,, Prof. Dr. med.</last_name>
      <phone>+41 061 328 68 10</phone>
      <email>sarah.tschudin@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Julia Herrmann</last_name>
      <email>julia.herrmann@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibiotic resistance</keyword>
  <keyword>Ambler class C beta-lactamase (AmpC)</keyword>
  <keyword>carbapenem resistance</keyword>
  <keyword>minimum inhibitory concentrations (MICs)</keyword>
  <keyword>cefepime</keyword>
  <keyword>piperacillin/tazobactam</keyword>
  <keyword>carbapenem</keyword>
  <keyword>Clostridium difficile infections</keyword>
  <keyword>epidemiological trends</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

